CASC8 Information

CASC8 is a pioneering biotech company developing a first-in-class regenerative cell therapy that directly restores damaged heart muscle —addressing the root cause of heart failure rather than managing symptoms. With strong preclinical validation and a scalable, off-the-shelf platform, CASC8 is positioned to transform a €260B global market by shifting cardiac care from chronic treatment to true tissue repair